[Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication]. / De ziekte van Behçet en de mogelijkheden van moderne tumornecrosisfactor-remmende medicatie.
Ned Tijdschr Geneeskd
; 150(13): 705-9, 2006 Apr 01.
Article
en Nl
| MEDLINE
| ID: mdl-16623340
A 25-year-old woman was admitted after having had a fever for one month, headache, nausea, vomiting, dysarthria and right-sided hemiparesis. A 35-year-old man was admitted because of severe loss of vision and a history of focal retinochoroiditis. Both were suffering from Behçet's disease. Behçet's disease can present with systemic symptoms that might be related to aberrant T-cell functions. It is treated with a variety of immunoregulatory drugs. Recently, treatment with tumour necrosis factor (TNF) alpha-inhibiting molecular designed drugs such as infliximab or etanercept has improved the therapeutic prospective of Behçet patients. Both of the patients described above developed refractory disease and responded to treatment with these new drugs.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Síndrome de Behçet
/
Factor de Necrosis Tumoral alfa
/
Inmunosupresores
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
Nl
Revista:
Ned Tijdschr Geneeskd
Año:
2006
Tipo del documento:
Article
Pais de publicación:
Países Bajos